Recognizing Mycoplasma pneumoniae early in children: a clinico-laboratory pattern and a simple hematology clue

Abstract

Background: Early diagnosis of Mycoplasma pneumoniae pneumonia (MPP) is challenging because its presentation overlaps with viral and typical bacterial pneumonia. Although polymerase chain reaction (PCR) is the diagnostic standard, it is not routinely available in most Indian laboratories, leaving clinicians dependent on serology, which has recognized limitations. We aimed to identify a practical clinicolaboratory pattern, including a simple hematological clue, for early recognition of pediatric MPP.

Methods: This retrospective observational study included 60 children managed during a three-month community outbreak of clinically suspected and/or serologically confirmed MPP at a tertiary care pediatric center. Clinical, laboratory, radiographic, treatment and outcome data were reviewed, emphasizing automated complete blood count (CBC) abnormalities and their correction after incubating EDTA samples at 37°C.

Results: Children presented with prolonged fever, persistent dry cough, mild respiratory distress despite radiographic pneumonia and poor response to β-lactam antibiotics. Inflammatory markers were modestly elevated, with normal or mildly increased leukocyte counts. Chest radiographs showed lower lobe consolidation, although bilateral pneumonia, pleural effusion, lobar collapse and severe extrapulmonary manifestations also occurred. Several children showed spuriously elevated mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC) with reduced red blood cell counts due to cold agglutinin-mediated agglutination, which normalized after warming samples to 37°C. Most improved rapidly after azithromycin or doxycycline.

Conclusions: Recognition of a characteristic clinicolaboratory pattern, together with reversible cold agglutinin-mediated CBC abnormalities, may facilitate early suspicion of MPP where molecular diagnostics are unavailable. Awareness of this simple hematological clue may enable earlier targeted therapy, reduce unnecessary β-lactam exposure and improve outcomes.